PerkinElmer
check quantity

IntegriSense 750 Fluorescent Imaging Agent

Near-infrared (NIR) fluorescent agent for in vivo imaging and other applications. 

部件号 NEV10873
立即购买

请输入有效的数量

请登录后再添加至收藏夹

购物车为空

项目已成功添加到购物车

For laboratory use only. This product is intended for animal research only and not for use in humans.

详情 信息

IntegriSense™ 750 is a targeted fluorescent imaging agent comprising a potent, selective non-peptide small molecule integrin avb3 antagonist and a near- infrared (NIR) fluorochrome. IntegriSense 750 has a shorter half life in tissue than IntegriSense 680. IntegriSense 750 washes out of tissues in ~ 96 hours to permit more frequent reinjection of the agent in longitudinal studies. This agent has been developed to enable in vivo visualization and quantification of integrin avb3 in tumor cells as well as in neovasculature, to monitor tumor growth, tumor angiogenesis, and treatment efficacy. Absorbance and fluorescence emission spectra of IntegriSense 750 in 1x PBS.

规格

荧光剂类型 Targeted
光学成像分类 Fluorescence Imaging
产品品牌名称 IntegriSense
包装量 1.0 Units
运输条件 蓝冰
治疗领域 Angiogenesis, Atherosclerosis, Oncology/Cancer
产品尺寸 1 Vial (10 doses)
波长 750 nm
资源,活动及更多信息
  • 所有

产品手册

应用文献

In Vivo Imaging of Atherosclerosis Disease Using FMT

Current means of measuring disease in preclinical models of atherosclerosis include ex vivo assessment of disease tissues post-mortem and non-invasive imaging primarily of structural and anatomic features of lesions, in vivo. A non-invasive, quantitative means of imaging known biologic profiles associated with atherosclerotic disease, in vivo, would enable a robust additional understanding and analysis of disease progression and therapeutic response in research and drug development. We report the utility of the near infrared (NIR) protease-sensing, ProSense® 750 Fluorescent Pre-clinical Imaging Agent, in combination with the FMT® 2500 Quantitative Pre-clinical Imaging System for the non-invasive quantitative measurement of atherosclerotic disease biology and related response to therapy in apolipoprotein (apo) E-deficient mice in vivo. FMT (Fluorescence Molecular Tomography) imaging measured significant increases in aortic region protease activity with a range of values that were comparable to the range seen in the ex vivo aortic arches assessed by fluorescence reflectance imaging (FRI).

PDF 1 MB
Multiplex 2D Imaging of NIR Molecular Imaging Agents on the IVIS SpectrumCT and FMT 4000

Epifluorescence (2D) imaging of superficially,implanted mouse tumor xenograft models offers,a fast and simple method for assessing tumor,progression or response to therapy. This approach,for tumor assessment requires the use of near,infrared (NIR) imaging agents specific for different,aspects of tumor biology, and this Application,Note highlights the ease and utility of multiplex,NIR fluorescence imaging to characterize the,complex biology within tumors growing in a living,mouse. IntegriSense™ 750 detects avb3 integrin,expression, BombesinRSense™ 680 detects the upregulation of bombesin receptor,(associated with tumor proliferation), Transferrin-Vivo™ 750 detects increases in,transferrin receptor (due to increased iron metabolism), MMPSense® 680 is activated,by disease-related matrix-metalloproteases (secreted by tumor cells and tumor,associated macrophages), and ProSense® 750EX detects increases in cathepsin,activity (elevated in lysosomes of tumors and inflammatory cells). OsteoSense® 680,a bone turnover imaging agent, was used as a non-tumor imaging control. These,and multiple other PerkinElmer imaging agents, can be used to characterize tumor,biology, and in this set of studies the data shows that two different tumors, HeLa,(cervical cancer) and 4T1 (breast cancer), can differ in their pattern of labeling,intensities for six distinct biological imaging agents. Such an approach is likely to,prove valuable for the full biological characterization of tumors during progression,metastasis, or response to treatment.

PDF 4 MB

技术说明

IntegriSense 750 (Protocol)

IntegriSense 750 in vivo fluorescent agent protocol

PDF 258 KB
IntegriSense™ 750 (Data Sheet)

IntegriSense™ 750 is a targeted fluorescence imaging agent comprising a potent, selective non-peptide small molecule integrin avß3 antagonist and a near-infrared (NIR) fluorochrome. This agent has been developed to enable in vivo visualization and quantification of integrin avß3 expressed in tumor cells as well as in neovasculature, to monitor tumor growth, tumor angiogenesis, and treatment efficacy.

PDF 57 KB